Next generation proteomic cancer detection via portable liquid biopsy

What will change?

What will change?

Stacks Image 18

Current

Future

  • Thomas coughs up blood and gets chest x-ray for evaluation. A chest CT scan for further evaluation is strongly recommended.
  • An invasive tissue biopsy of his lung and lymph nodes is performed for both diagnosis and staging. Stage 3 lung cancer is discovered.
  • He gets chemoradiotherapy and more imaging prior to surgery. Thomas continues chemoradiotherapy afterwards while also trying targeted therapies and immunotherapies under trial.
  • He gets more imaging during treatment to track disease progression. Thomas eventually passes away some time later.
  • Chloe is found to have lung cancer through liquid biopsy screening and follows up with chest CT scan for further evaluation.
  • It is revealed that she has solitary lung mass with no enlarged lymph nodes. Being caught earlier with stage 2 lung cancer, the surgery is curative.
  • She therefore receives a combination of targeted therapy and immunotherapy based on proteomic profile of tumor (if need be, it includes chemoradiotherapy, but as a second-line of treatment only due to side effects).
  • She remains cancer-free with treatment monitoring and prognostic evaluation done by liquid biopsy-based tests.
Stacks Image 47

Current

  • Thomas coughs up blood and gets chest x-ray for evaluation. A chest CT scan for further evaluation is strongly recommended.
  • An invasive tissue biopsy of his lung and lymph nodes is performed for both diagnosis and staging. Stage 3 lung cancer is discovered.
  • He gets chemoradiotherapy and more imaging prior to surgery. Thomas continues chemoradiotherapy afterwards while also trying targeted therapies and immunotherapies under trial.
  • He gets more imaging during treatment to track disease progression. Thomas eventually passes away some time later.
Stacks Image 55

Future

  • Chloe is found to have lung cancer through liquid biopsy screening and follows up with chest CT scan for further evaluation.
  • It is revealed that she has solitary lung mass with no enlarged lymph nodes. Being caught earlier with stage 2 lung cancer, the surgery is curative.
  • She therefore receives a combination of targeted therapy and immunotherapy based on proteomic profile of tumor (if need be, it includes chemoradiotherapy, but as a second-line of treatment only due to side effects).
  • She remains cancer-free with treatment monitoring and prognostic evaluation done by liquid biopsy-based tests.

What is a protein biomarker?

What is a protein biomarker?

Although progress in cancer genomics has been rapid during the past few years, it only provides us with a glimpse of what may occur as dictated by the genetic code. In reality, we still need to measure what is happening in a patient in real time, which means finding tell-tale proteins that provide insight into the biological processes of cancer development. This is because genes are only the "recipes" of the cell, while the proteins encoded by the genes are ultimately the functional players that drive both normal and disease physiology.
Although progress in cancer genomics has been rapid during the past few years, it only provides us with a glimpse of what may occur as dictated by the genetic code. In reality, we still need to measure what is happening in a patient in real time, which means finding tell-tale proteins that provide insight into the biological processes of cancer development. This is because genes are only the "recipes" of the cell, while the proteins encoded by the genes are ultimately the functional players that drive both normal and disease physiology.
Although progress in cancer genomics has been rapid during the past few years, it only provides us with a glimpse of what may occur as dictated by the genetic code. In reality, we still need to measure what is happening in a patient in real time, which means finding tell-tale proteins that provide insight into the biological processes of cancer development. This is because genes are only the "recipes" of the cell, while the proteins encoded by the genes are ultimately the functional players that drive both normal and disease physiology.

Why does it matter?

Why does it matter?

There are already dozens of FDA-approved protein biomarkers whose concentration is correlated with the presence of cancer. There are over thousands of candidate protein biomarkers where we found evidence of a quantitative change in some human cancer (see Early Detection Research Network list). Proteins have a much more predictive power than genes and, when a lot of them are simultaneously measured from the same patient’s biosample (such as blood serum), we could reach cancer diagnostic probability levels converging to 100% without any invasive tissue biopsy.
There are already dozens of FDA-approved protein biomarkers whose concentration is correlated with the presence of cancer. There are over thousands of candidate protein biomarkers where we found evidence of a quantitative change in some human cancer (see Early Detection Research Network list). Proteins have a much more predictive power than genes and, when a lot of them are simultaneously measured from the same patient’s biosample (such as blood serum), we could reach cancer diagnostic probability levels converging to 100% without any invasive tissue biopsy.

What can we expect?

What can we expect?

This process shall eventually take over in order to fully establish the presence or the development level of cancer in the future while allowing early stage screening at doctor's office and, then, your home. We believe our diagnostic device prototype could be one of the best large-scale solutions to empower doctors and patients to benefit from the proteomics revolution through liquid biopsy.
This process shall eventually take over in order to fully establish the presence or the development level of cancer in the future while allowing early stage screening at doctor's office and, then, your home. We believe our diagnostic device prototype could be one of the best large-scale solutions to empower doctors and patients to benefit from the proteomics revolution through liquid biopsy.